The FDA has started a priority review of Sanofi and Regeneron’s Dupixent as a treatment for chronic obstructive pulmonary disease (COPD), which could become the first new
In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).
A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for
AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan
French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung
Signs that the Federal Trade Commission (FTC) in the US may be softening its stance on pharma deals seem to have been misread, as the regulator has now sued to block Sanof
UK researchers say they have developed an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.